Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 191-196 , December 2008

Adjuvant Therapy for Node-Positive Colon Cancer

  • Haider A. Shirazi, MD, MS

      Affiliations

    • Department of Radiation Oncology, Chicago, Illinois
    • ,
  • Mamta Singhvi, MD

      Affiliations

    • Department of Radiation Oncology, Chicago, Illinois
    • ,
  • William Small Jr, MD

      Affiliations

    • Department of Radiation Oncology, Chicago, Illinois
    • ,
  • Al B. Benson III, MD

      Affiliations

    • Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
    • Corresponding Author InformationAddress reprint requests to: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 N. St. Clair, Galter Patient Pavilian, 21st Floor, Chicago, IL 60611

References 

  1. Haller DG, Catalano PJ, Macdonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:(abstr 982)
  2. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6. New York, NY: Springer-Verlag; 2002;
  3. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004;22:1797–1806
  4. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912–2919
  5. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739–1757
  6. Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 1999;86:2436–2446
  7. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206
  8. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  9. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–326
  10. Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008;26:(May 20 suppl; abstr 4008)
  11. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? (A statistical perspective). Semin Oncol. 2001;28(1 suppl 1):20–24
  12. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–3461
  13. Poplin E, Benedetti J, Estes N, et al. Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153). Proc Am Soc Clin Oncol. 2000;19:(abstr 931)
  14. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;16:1859–1865
  15. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (PETACC-3). J Clin Oncol. 2005;23:8
  16. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2+CPT-11 versus LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol. 2005;23:3502
  17. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005;23:246s;(suppl; abstr 3501)
  18. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  19. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Onc. 2007;ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 suppl), 4007, 2007
  20. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol. 2005;23:3500
  21. Wolmark N, Wieand S, Kuebler PJ, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. J Clin Oncol. 2008;26:(May 20 suppl: abstr LBA4005)
  22. Wolmark N, Wieand S, Lembersky B, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. Proc Am Soc Clin Oncol. 2004;22:14S;(abstr 3508)
  23. Cassidy J, Scheithauer W, McKendrick J, et al. X-ACT study investigators Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proc Am Soc Clin Oncol. 2004;22:14S;(abstr 3509)
  24. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–8670
  25. Willett C, Goldberg S, Shellito P, et al. Does postoperative radiation play a role in the adjuvant therapy of stage T4 colon cancer?. Cancer J Sci Am. 1999;5(4):242–247
  26. Gunderson LL, Nelson H, Martenson J, et al. Locally advanced primary colorectal cancer: Intraoperative electron and external beam irradiation +/− 5-FU. Int J Radiat Oncol Biol Phys. 1997;37:601–614
  27. Martenson JA, Willett CG, Sargent DJ, et al. A phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of Intergroup protocol 0130. J Clin Oncol. 2004;22(16):
  28. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26:(May 20 suppl; abstr 2)

PII: S1043-1489(08)00055-9

doi: 10.1053/j.scrs.2008.09.005

Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 191-196 , December 2008

Article Tools

* Image Usage & Resolution